CHALFONT ST. GILES, UK -- 19 November 2013 -- GE Healthcare Life Sciences, (NYSE: GE) and Cellectis Group (Alternext: ALCLS), the global genome engineering specialist, announced today that GE Healthcare has licenced Cellectis to develop, manufacture and sell models derived from stem cells for use in drug discovery and toxicity screening.
* Consumer awareness and cultural barriers surrounding screening putting lives at risk
* 15 million years of 'healthy life' were lost worldwide in 2008 due to women dying early or being ill with the disease
Chalfont St. Giles, U.K. --- October 15, 2013. Rising breast cancer incidence and mortality represent a significant and growing threat for the developing world, according to a new global study commissioned by GE Healthcare.
business unit
tags
MILWAUKEE - GE Healthcare announced today that its Discovery* PET/CT 690 and PET VCAR 2.0 were used by Professor Patrick Flamen of the Institut Jules Bordet in Brussels in capturing the Society of Nuclear Medicine and Molecular Imaging 2013 "Image of the Year."
Professor Flamen's winning scan illustrated the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease. It was selected as the winning image from more than 2,000 studies.
business unit
tags
WAUKESHA, WI -- July 30, 2013-- GE Healthcare, a unit of General Electric Company (NYSE:GE), announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval application (PMA[1]) for GE Breast Tomosynthesis, an option of the Senographe* Essential system.